Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease

Objective: Neoadjuvant chemotherapy (NACT) allows for a more frequent use of breast-conservative surgery; it is also an in vivo model of individual tumor sensitivity which permits to determine new prognostic factors to personalize the therapeutic approach. Methods: Between 2000 and 2012, 318 patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology 2015-04, Vol.88 (5), p.261-272
Hauptverfasser:	Mombelli, Sarah, Kwiatkowski, Fabrice, Abrial, Catherine, Wang-Lopez, Qian, de Boissieu, Paul, Garbar, Christian, Bensussan, Armand, Curé, Hervé
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Adult Aged Aged, 80 and over Anthracyclines - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - epidemiology Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery Chemotherapy Chemotherapy, Adjuvant Clinical Study Confounding Factors (Epidemiology) Cyclophosphamide - administration & dosage Development and progression Disease-Free Survival Drug Administration Schedule Drug therapy Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Follow-Up Studies France - epidemiology Humans Kaplan-Meier Estimate Lymphatic Metastasis Mastectomy, Segmental Medical prognosis Metastasis Middle Aged Neoadjuvant Therapy - methods Neoplasm Staging Neoplasm, Residual - epidemiology Patient outcomes Prognosis Retrospective Studies Risk Factors Taxoids - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!